<!– –> <!– Page Last Updated: 04/01/2014 –> Page Last Updated: 04/01/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA clarifies Warning about Pediatric Use of Revatio (sildenafil) for Pulmonary Arterial Hypertension
<!– –> <!– Page Last Updated: 03/31/2014 –> Page Last Updated: 03/31/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Opioid Patient-Prescriber Agreement
A Tool for Shared Decision-Making in the Treatment of Pain As part of a pain treatment regimen, patients may be prescribed opioid analgesics. Opioids, like all drugs, have risks. Prescribing errors and inappropriate use of opioid analgesics increase risk and can lead to serious harm, including death. This harm is preventable. In April 2011, FDA Safe…
FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia
<!– –> <!– Page Last Updated: 03/06/2014 –> Page Last Updated: 03/06/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files
<!– –> <!– Page Last Updated: 02/26/2014 –> Page Last Updated: 02/26/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
How to Report a Shortage or Supply Issue
<!– –> <!– Page Last Updated: 02/14/2014 –> Page Last Updated: 02/14/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Small Business and Industry Education Series
<!– –> <!– Page Last Updated: 02/13/2014 –> Page Last Updated: 02/13/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA analizará el riesgo de insuficiencia cardiaca con el medicamento para la diabetes saxagliptina (comercializado como Onglyza y Kombiglyze XR)
<!– –> <!– Page Last Updated: 02/12/2014 –> Page Last Updated: 02/12/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR)
<!– –> <!– Page Last Updated: 02/11/2014 –> Page Last Updated: 02/11/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA evalúa riesgo de derrame, ataque cardiaco y muerte por usar productos con testosterona aprobados por la FDA
<!– –> <!– Page Last Updated: 02/06/2014 –> Page Last Updated: 02/06/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.